Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Washington University Center for Diabetes Translation Research Administrative Core in Diabetes Research Core Resource Report Resource Website |
Washington University Center for Diabetes Translation Research Administrative Core in Diabetes Research Core (RRID:SCR_015235) | access service resource, core facility, service resource, resource | Management core whose main functions include organizing and managing membership committees, coordinating communication with the NIH and other research bases, and overseeing the use of funds. | diabetes research core, administrative core, management resource, funding resource |
is listed by: NIDDK Information Network (dkNET) has parent organization: Washington University in St. Louis; Missouri; USA has parent organization: Washington University Center for Diabetes Translation Research is organization facet of: Washington University Center for Diabetes Translation Research |
Diabetes | NIDDK P30DK092950 | Available to the CDTR community | SCR_015235 | 2026-02-15 09:21:10 | 0 | ||||||||
|
Washington University Center for Diabetes Translation Research Solutions to Diabetes in Black Americans Core Resource Report Resource Website |
Washington University Center for Diabetes Translation Research Solutions to Diabetes in Black Americans Core (RRID:SCR_015215) | access service resource, core facility, service resource, resource | Core facility whose services include consultation about the challenges that Black Americans face regarding diet and food advertising, study design and implementation assistance, and positing relevant questions to the larger core for relevant research questions. | diabetes translation research, diabetes in black americans, community engagement, community outreach, food advertising |
is listed by: NIDDK Information Network (dkNET) has parent organization: Washington University in St. Louis; Missouri; USA has parent organization: Washington University Center for Diabetes Translation Research is organization facet of: Washington University Center for Diabetes Translation Research |
Diabetes | NIDDK P30DK092950 | Available to the CDTR community | SCR_015215 | 2026-02-15 09:21:09 | 0 | ||||||||
|
MMPC-Vanderbilt University School of Medicine Cardiovascular Pathophysiology Core Resource Report Resource Website |
MMPC-Vanderbilt University School of Medicine Cardiovascular Pathophysiology Core (RRID:SCR_015353) | access service resource, core facility, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 6th,2023. Core whose objective is to provide investigators at Vanderbilt and outside institutions a means to accurately assess cardiovascular phenotypes in mouse models of diabetes and metabolic disease. The CPC uses validated approaches and state-of-the-art instrumentation that allow for sensitive screening of phenotypic variations. | cardiovascular phenotype, cardiovascular mouse model, diabetes mouse model, metabolic mouse model |
is listed by: NIDDK Information Network (dkNET) has parent organization: National Mouse Metabolic Phenotyping Centers has parent organization: MMPC-Vanderbilt University School of Medicine is organization facet of: MMPC-Vanderbilt University School of Medicine |
Diabetes, metabolic disease | NIDDK U24 DK059637 | THIS RESOURCE IS NO LONGER IN SERVICE | SCR_015353 | 2026-02-15 09:20:52 | 0 | ||||||||
|
MMPC-University of California Davis Energy Balance Exercise and Behavior Core Resource Report Resource Website 1+ mentions |
MMPC-University of California Davis Energy Balance Exercise and Behavior Core (RRID:SCR_015364) | access service resource, core facility, service resource, resource | Core that provides investigators with services to accurately measure the major components of energy balance in their mouse models and tests that allow investigators to examine physiological factors that may influence food intake or energy expenditure. | energy balance, exercise and behavior, obesity |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of California at Davis; California; USA has parent organization: National Mouse Metabolic Phenotyping Centers has parent organization: MMPC-University of California Davis is organization facet of: MMPC-University of California Davis |
Obesity, Diabetes, metabolic disease | NIDDK DK092993 | Available to the research community | SCR_015364 | 2026-02-15 09:21:14 | 6 | ||||||||
|
Rare and Atypical Diabetes Network Resource Report Resource Website 1+ mentions |
Rare and Atypical Diabetes Network (RRID:SCR_024732) | RADIANT | portal, database, data or information resource, topical portal, disease-related portal | Portal dedicated to characterizing, discovering and defining rare and atypical forms of diabetes. Network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health. | USA, universities network, hospitals and clinics network, characterizing atypical diabetes, discovering atypical diabetes, defining atypical diabetes, rare and atypical forms of diabetes, atypical diabetes, |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository |
rare and atypical forms of diabetes, Diabetes | NIDDK | Restricted | SCR_024732 | Rare and Atypical DIAbetes NeTwork | 2026-02-15 09:22:47 | 2 | ||||||
|
reMYND Resource Report Resource Website 1+ mentions |
reMYND (RRID:SCR_003824) | reMYND | commercial organization | Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation. | protein misfolding | Alzheimer's disease, Parkinson's disease, Diabetes | IWT ; Michael J. Fox Foundation for Parkinson's Research |
nlx_158130 | SCR_003824 | reMYND NV | 2026-02-14 02:00:53 | 1 | |||||||
|
Diamyd Medical Resource Report Resource Website 1+ mentions |
Diamyd Medical (RRID:SCR_003930) | DMYD B | commercial organization | A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden''s largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders. | pharmaceutical, drug development, drug | is related to: Pharma-Planta Consortium | Type 1 diabetes, Diabetes | nlx_158298 | SCR_003930 | Diamyd Medical AB | 2026-02-14 02:00:33 | 2 | |||||||
|
Foundation for the National Institutes of Health Resource Report Resource Website 1000+ mentions |
Foundation for the National Institutes of Health (RRID:SCR_004493) | FNIH | institution | A public charity whose mission is to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. Its vision is Building Partnerships for Discovery and Innovation to Improve Health. The FNIH draws together the world''s foremost researchers and resources, pressing the frontier to advance critical discoveries. They are recognized as the number-one medical research charity in the countryleveraging support, and convening high level partnerships, for the greatest impact on the most urgent medical challenges we face today. Grants are awarded as part of a public-private partnership with the National Heart, Lung, and Blood Institute (NHLBI) on behalf of The Heart Truth in support of women''s heart health education and research. Funding for the Community Action Program is provided by the FNIH through donations from individuals and corporations including The Heart Truth partners Belk Department Stores, Diet Coke, and Swarovski. Successful biomedical research relies upon the knowledge, training and dedication of those who conduct it. Bringing multiple disciplines to bear on health challenges requires innovation and collaboration on the part of scientists. Foundation for NIH partnerships operate in a variety of ways and formats to recruit, train, empower and retain their next generation of researchers. From lectures and multi-week courses, to scholarships and awards through fellowships and residential training programs, their programs respond to the needs of scientists at every level and stage in their careers. | biomedical research |
is related to: Osteoarthritis Biomarkers Project (OABP) is parent organization of: Biomarkers Consortium is parent organization of: Observational Medical Outcomes Partnership is parent organization of: Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus is parent organization of: Accelerating Medicines Partnership - Alzheimers is parent organization of: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) is parent organization of: Genetic Association Information Network (GAIN) |
Type 1 diabetes, Type 2 diabetes, Diabetes, Metabolic disease, Alzheimer's disease, Schizophrenia, Prostate cancer, Demantia, Muscular dystrophy, Tuberculosis, HIV, Parkinson's disease, Osteoarthritis, Age-related eye disease, Visceral leishmaniasis, Undiagnosed disease, Cancer, Non-small cell lung cancer, Malaria, Systemic lupus erythematosus, COVID-19, Acute lymphoblastic leukemia | ISNI: 0000 0000 9836 9834, Wikidata: Q16837497, nlx_143768, Crossref funder ID: 100000009, grid.428807.1 | https://ror.org/00k86s890 | SCR_004493 | Foundation for NIH | 2026-02-14 02:00:44 | 1788 | ||||||
|
Ontology of Geographical Region Resource Report Resource Website |
Ontology of Geographical Region (RRID:SCR_010398) | OGR | data or information resource, ontology, controlled vocabulary | Ontology that is used with other ontologies to represent the genetic susceptibility factors of diabetes. This OWL ontology classified the geograhical regions related vocabularies extracted from UMLS. | owl | is listed by: BioPortal | Diabetes | nlx_157530 | SCR_010398 | 2026-02-14 02:01:57 | 0 | ||||||||
|
T1D Exchange Resource Report Resource Website 10+ mentions |
T1D Exchange (RRID:SCR_014532) | commercial organization | Provides access to resources T1D researchers need to conduct clinical studies. Data sets from their clinic registry is openly available, as are new study results. They also offer use of T1D Discovery Tool, which allows users to search different fields from registry data, and T1D Exchange Biobank, which offers specimen types such as serum, plasma, white blood cells, DNA, and RNA. | portal, dataset, type 1 diabetes, t1d, clinical, study, registry, data |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Knowledge Portal is parent organization of: T1D Exchange Biobank |
Type 1 diabetes, Diabetes | grid.461811.b | https://ror.org/016jvas21 | SCR_014532 | T1D Exchange Inc. | 2026-02-14 02:02:40 | 12 | |||||||
|
Accelerating Medicines Partnership Resource Report Resource Website 1+ mentions |
Accelerating Medicines Partnership (RRID:SCR_014927) | AMP | group | Partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical companies and non-profit organizations whose goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. The group explores three major areas of disease: diabetes, Alzheimer's disease, and rheumatoid arthritis and lupus. | group, partnership, nih, fda, medicine, diabetes, alzheimers, alzheimer's, rheumatoid arthritis, lupus |
has parent organization: National Institutes of Health is parent organization of: Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus is parent organization of: Accelerating Medicines Partnership - Alzheimers is parent organization of: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) |
diabetes, Alzheimer's disease, rheumatoid arthritis, lupus | SCR_014927 | Accelerating Medicines Partnership (AMP) | 2026-02-14 02:02:46 | 3 | ||||||||
|
American Diabetes Association Resource Report Resource Website 1000+ mentions |
American Diabetes Association (RRID:SCR_004526) | ADA | non profit organization | The mission of the American Diabetes Association (ADA) is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. We lead the fight against the deadly consequences of diabetes and fight for those affectedby diabetes. * We fund research to prevent, cure and manage diabetes. * We deliver services to hundreds of communities. * We provide objective and credible information. * We give voice to those denied their rights because of diabetes. | diabetes, diabetes mellitus, type 1 diabetes, type 2 diabetes, gestational diabetes | Type 1 diabetes, Type 2 diabetes, Diabetes | Crossref funder ID: 100000041, ISNI: 0000 0001 1033 6008, Wikidata: Q4743610, nlx_143804, grid.427608.f | https://ror.org/04f6cgz95 | SCR_004526 | 2026-02-14 02:00:42 | 1256 | ||||||||
|
Helmsley Charitable Trust Resource Report Resource Website |
Helmsley Charitable Trust (RRID:SCR_005111) | Helmsley Charitable Trust | funding resource | The Leona M. and Harry B. Helmsley Charitable Trust supports a broad spectrum of healthcare and medical research-based programs. The areas supported include Type 1 Diabetes, Digestive Diseases, Rural Healthcare, Cardiology, and a range of other programs and institutions. | grant, health, medical research, type 1 diabetes, digestive disease, rural healthcare, cardiology | is parent organization of: Helmsley Cellular Research Hub | Type 1 diabetes, Diabetes, Crohn's disease | nlx_144118 | SCR_005111 | Leona M. and Harry B. Helmsley Charitable Trust, Leona M. Harry B. Helmsley Charitable Trust | 2026-02-14 02:01:04 | 0 | |||||||
|
Merck Resource Report Resource Website 10000+ mentions |
Merck (RRID:SCR_001287) | Merck | commercial organization | An American pharmaceutical company aiming to make a difference in the lives of people globally through their medicines, vaccines, biologic therapies and animal health products. | pharmaceutical, merck sharp & dohme corp, merck sharp and dohme corp, merck sharp and dohme, merck sharp & dohme corp., msd, medicine, endocrinology, neuroscience, oncology, respiratory, immunology, vaccine, animal health, veterinary |
uses: Kaggle uses: Tableau Desktop uses: FluoroFinder is affiliated with: European Federation of Pharmaceutical Industries and Associations is related to: eTRIKS is related to: OncoTrack is related to: European Lead Factory is related to: GetReal is related to: Investigator Databank is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: ORBITO is related to: PharmaCog is related to: Asian Cancer Research Group is related to: Open PHACTS is related to: Collaboratory of AIDS Researchers for Eradciation (CARE) is parent organization of: MEDINA Foundation is parent organization of: Asian Cancer Research Group is parent organization of: Asia Training Consortium |
Diabetes, Cancer, Cardiovascular disease, Infectious disease | Crossref funder ID: 100004334, grid.417993.1, Wikidata: Q247489, ISNI: 0000 0001 2260 0793, nlx_152409 | https://ror.org/02891sr49 | SCR_001287 | Merck and Co., Merck and Co. Inc., Merck & Co. Inc., Merck & Co. | 2026-02-14 01:59:57 | 10277 | ||||||
|
Heptares Therapeutics Resource Report Resource Website |
Heptares Therapeutics (RRID:SCR_000499) | commercial organization | A drug discovery company focused on small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. They are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilization, structure determination, and fragment-based discovery. Their partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Their objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, ADHD and chronic migraine. | g-protein coupled receptor, small molecule, drug, biotechnology, medicine, antibody, drug discovery | is related to: Kinetics for Drug Discovery | Alzheimer's disease, Schizophrenia, Diabetes, Attention deficit-hyperactivity disorder, Chronic migraine | nlx_158498, grid.450873.d, ISNI: 0000 0004 0456 4700 | https://ror.org/051fk5x88 | SCR_000499 | Heptares Therapeutics Limited, Heptares Therapeutics Ltd, Heptares | 2026-02-14 01:59:44 | 0 | |||||||
|
Sequencing of Idd regions in the NOD mouse genome Resource Report Resource Website 1+ mentions |
Sequencing of Idd regions in the NOD mouse genome (RRID:SCR_001483) | Sequencing of Idd regions in the NOD mouse genome | data or information resource, data set, resource | Genetic variations associated with type 1 diabetes identified by sequencing regions of the non-obese diabetic (NOD) mouse genome and comparing them with the same areas of a diabetes-resistant C57BL/6J reference mouse allowing identification of single nucleotide polymorphisms (SNPs) or other genomic variations putatively associated with diabetes in mice. Finished clones from the targeted insulin-dependent diabetes (Idd) candidate regions are displayed in the NOD clone sequence section of the website, where they can be downloaded either as individual clone sequences or larger contigs that make up the accession golden path (AGP). All sequences are publicly available via the International Nucleotide Sequence Database Collaboration. Two NOD mouse BAC libraries were constructed and the BAC ends sequenced. Clones from the DIL NOD BAC library constructed by RIKEN Genomic Sciences Centre (Japan) in conjunction with the Diabetes and Inflammation Laboratory (DIL) (University of Cambridge) from the NOD/MrkTac mouse strain are designated DIL. Clones from the CHORI-29 NOD BAC library constructed by Pieter de Jong (Children's Hospital, Oakland, California, USA) from the NOD/ShiLtJ mouse strain are designated CHORI-29. All NOD mouse BAC end-sequences have been submitted to the International Nucleotide Sequence Database Consortium (INSDC), deposited in the NCBI trace archive. They have generated a clone map from these two libraries by mapping the BAC end-sequences to the latest assembly of the C57BL/6J mouse reference genome sequence. These BAC end-sequence alignments can then be visualized in the Ensembl mouse genome browser where the alignments of both NOD BAC libraries can be accessed through the Distributed Annotation System (DAS). The Mouse Genomes Project has used the Illumina platform to sequence the entire NOD/ShiLtJ genome and this should help to position unaligned BAC end-sequences to novel non-reference regions of the NOD genome. Further information about the BAC end-sequences, such as their alignment, variation data and Ensembl gene coverage, can be obtained from the NOD mouse ftp site. | genome, sequencing, genome sequencing, insulin-dependent diabetes, c57bl/6j, single nucleotide polymorphism, genetic variation, bacterial artificial chromosome, sequence, gene, animal model, clone, annotation, contig |
lists: VEGA is listed by: NIDDK Information Network (dkNET) has parent organization: Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
Type 1 diabetes, Diabetes | NIAID AI 15416; NIDDK ; JDRF |
PMID:23729657 | Free, Freely available | nlx_152738 | http://www.sanger.ac.uk/resources/mouse/nod/ | SCR_001483 | Sequencing of Insulin-dependent diabetes regions in the NOD mouse genome | 2026-02-14 02:05:20 | 1 | |||
|
National Diabetes Education Program Resource Report Resource Website 10+ mentions |
National Diabetes Education Program (RRID:SCR_001477) | NDEP | training resource, resource | Federal government public education program that promotes diabetes prevention and control. They aim to reduce the morbidity and mortality associated with diabetes and its complications. The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention and over 200 partner organizations. Target audiences include people with diabetes and those at risk, including the racial and ethnic populations disproportionately affected by the disease, health care providers and payers and purchasers of health care. | treatment, outcome, diabetes, diagnosis, prevention, blood glucose level, complication, education, disease-related portal |
is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Type 2 diabetes, Diabetes | NIDDK N02DK72927-8-0-1 | Free, Freely available | nlx_152708 | SCR_001477 | 2026-02-14 02:07:18 | 38 | ||||||
|
Diabetes Prevention Program Outcomes Study Resource Report Resource Website |
Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) | DPPOS | data or information resource, clinical trial, database, resource | Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants. | adult human, late adult human, male, female, caucasian, african-american, hispanic american, asian, pacific islander-american, american indian, metformin, microangiopathic, neuropathic, outcome, placebo, diabetic retinopathy, diabetic neuropathy, albuminuria, renal failure, macrovascular disease, cardiovascular disease, atherosclerosis, risk factor, amputation, hospitalization, physical activity, nutrition, body mass, obesity, dietary behavior, exercise behavior, physical functioning, quality of life, health care cost, cognitive performance, urinary incontinence, observational, microvascular disease, blood, dna |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: George Washington University; Washington D.C.; USA |
Type 2 diabetes, Diabetes | NIDDK U01DK048514; NIDDK U01DK048437; NIDDK U01DK048413; NIDDK U01DK048406; NIDDK U01DK048380; NIDDK U01DK048397 |
Free, Freely available | nlx_152800 | SCR_001502 | 2026-02-14 02:07:27 | 0 | ||||||
|
Southwestern NMR Center for In Vivo Metabolism Resource Report Resource Website 1+ mentions |
Southwestern NMR Center for In Vivo Metabolism (RRID:SCR_001429) | Southwestern NMR Center | biomedical technology research center, training resource | Biomedical technology research center that develops and applies new methods for analysis of metabolic networks in intact tissues, animals and human patients. The importance of understanding abnormal metabolism in common diseases such as cancer, diabetes and heart disease has long been appreciated. Because of constraints in technology, however, much of this research has been conducted in isolated systems where clinical relevance may be uncertain. Progress in magnetic resonance technology provides a foundation for major advances towards new ways of imaging metabolism in patients. These new techniques offer the advantage of imaging biochemical pathways without radiation. The focus of this Resource is to bring these technologies to a level where clinical research is feasible through the development of new MR contrast agents, NMR spectroscopy at high fields, and imaging of hyperpolarized 13C. | metabolic network, tissue, imaging, metabolism, nuclear magnetic resonance, magnetic resonance, nuclear magnetic resonance spectroscopy | has parent organization: University of Texas Southwestern Medical Center; Texas; USA | Cancer, Diabetes, Heart disease | NIBIB 5P41EB015908-28 | Free, Freely Available | nlx_152653 | SCR_001429 | Southwestern NMR Center for in vivo Metabolism - NIBIB | 2026-02-14 02:07:27 | 1 | |||||
|
A Whole Genome Admixture Scan for Type 2 Diabetes in African Americans Resource Report Resource Website 1+ mentions |
A Whole Genome Admixture Scan for Type 2 Diabetes in African Americans (RRID:SCR_006984) | data or information resource, data set | Genomic data set on Type 2 Diabetes in African-Americans derived via admixture mapping, a method for genome-wide association analysis based on admixture-generated linkage disequilibrium. This collaborative group has identified 1,478 African Americans with Type 2 Diabetes (T2D) from the Jackson Heart Study and Multiethnic Cohort Study, as well as 498 controls from the Jackson Heart Study who are normoglycemic despite high body mass index and older age. All samples were genotyped (using the Illumina BeadLab platform) for 1,291 polymorphic markers chosen to be extremely different in frequency between west Africans and European Americans. Evidence for association to diabetes at each marker as reported by the ANCESTRYMAP software are reported in the downloadable table. They calculate that this study has statistical power to detect loci where African or European ancestry on average confers multiplicative increased risk of 1.35-fold or more. The fact that they did not detect a statistically significant signal of association in the scan suggests that any genetic risk factors for T2D do not confer different risks due to ancestry that differ by this factor. The genome scan results are publicly available (Excel file) prior to publication so that researchers interested in the genetics of T2D can use the results of the scan to prioritize follow-up of any regions of interest. | admixture, genome, gwas, disequilibrium, normoglycemic, genotyped, polymorphic, marker, diabetes, clinical study, phenotype, african american, aging |
is related to: Jackson Heart Study has parent organization: Massachusetts Institute of Technology; Massachusetts; USA; |
Diabetes | Eli and Edythe L. Broad | Genome scan is available for download as CSV | nif-0000-30020 | SCR_006984 | Diabetes Genetics Initiative | 2026-02-14 02:07:23 | 1 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
